1) chronic myeloid leukemia
慢性髓性白血病
1.
In order to investigate the features of M bcr/abl and m bcr/abl fusion transcripts in patients with chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (SCT), M bcr/abl and m bcr/abl fusion transcripts were sequentially detected by RT PCR technique in 72 CML patients after SCT.
为研究慢性髓性白血病 (CML)异基因造血干细胞移植 (SCT)后M bcr/abl及m bcr/abl融合转录子表达特征 ,采用逆转录 聚合酶链反应 (RT PCR)技术测定 72例CML患者SCT后不同时间骨髓M bcr/abl及m bcr/abl融合转录子的表达。
2.
The crucial genetic event in Chronic myeloid leukemia is the generation of a t (9;22)(q34;qll) reciprocal chromosomal translocation in a hematopoietic stem cell.
慢性髓性白血病(Chronic myeloid leukemia, CML)是一种起源于多能干细胞的恶性增生性疾病，其最重要的细胞遗传学特征是存在特异性的Ph染色体，第9号染色体上的原癌基因c-ab1易位到第22号染色体的断点集中区(bcr)形成bcr-ab1融合基因，编码bcr-ab1融合蛋白(p210~(bcr-ab1))。
2) Chronic myelogenous leukemia
慢性髓性白血病
1.
Chronic myelogenous leukemia(CML)is a myeloproliferative disorder of pluripotent hematopoietic stem cells,whose cell genetic marker is Philadelphia(Ph) chromosome.
慢性髓性白血病(CML)属于多能造血干细胞恶性骨髓增生性疾病,费城(Ph)染色体是CML的细胞遗传学标志,90%以上CML患者骨髓细胞中发现有Ph染色体,经过20年的研究,CML患者的生存愈后得到了显著改善,特别是伊马替尼研制成功给治疗CML带来了很大飞跃。
3) CML
慢性髓性白血病
1.
CLONING AND EXPRESSION OF CML bcr-abl FUSION GENE FRAGMENT;
慢性髓性白血病bcr-abl融合基因的克隆与表达
2.
Targeting the tyrosine kinase activity of Bcr-Abl with STI571 is anattractive therapeutic strategy in chronic myelogenous leukemia (CML).
慢性髓性白血病是一种起源于造血多功能细胞的恶性增生性疾病,约占成人白血病的15%可分为慢性期﹑加速期﹑急变期,一般病程持续4年左右,随着疾病进展面对治疗逐渐不敏感。
4) chronic myeloid leukemia
慢性髓系白血病
1.
Quantitative analysis of Sokal s risk index in relation to2therapy protocols:their respective impact on clinical remission of chronic myeloid leukemia;
定量分析两种治疗方案与危险指数对慢性髓系白血病临床缓解率的影响
2.
This study was aimed to investigate the influences of interferonα(IFN-α)on expressions of CCR7,interleukin10(IL-10)and IL-12p70 in dendritic cells(DCs)from patients with chronic myeloid leukemia(CML).
本研究探讨干扰素α(IFN-α)对慢性髓系白血病(CML)来源树突状细胞(DC)表达趋化因子CCR7及分泌IL-10、IL-12P70的影响。
3.
The aim of this study was to investigate the effect of nonmyeloablative peripheral blood stem cell transplantation in treatment of chronic myeloid leukemia in chronic phase(CML-CP)and accelerated phasse(CML-AP).
本研究观察非清髓造血干细胞移植对慢性髓系白血病慢性期(CML-CP)、慢性髓系白血病加速期(CML-AP)的疗效。
5) chronic myelogenous leukemia
慢性髓系白血病
1.
Objective To evaluate vascular endothelial growth factor(VEGF) levels in the serum and the bone marrow cells of untreated acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) patients.
目的 探究急性髓系白血病 (AML)与慢性髓系白血病 (CML)血清及CML骨髓细胞VEGF含量的变化。
6) CML
慢性髓系白血病
1.
CML Cell Line K562 Cell Apoptosis Induced by Mangiferin;
芒果甙诱导慢性髓系白血病K562细胞凋亡
2.
SphK-1/S1P Signal Pathway in CML Cells;
慢性髓系白血病细胞中SphK-1/S1P信号通路的初步研究
3.
The specific antigen of chronic myeloid leukemia CML-28 was screened as objective antigen peptide by using magnetic microbeads as vector; the CML-28 epitope sequence (Vltfaldsv) was obtained by antigen epitope prediction software; this epitope was coupled with MHC molecu.
以磁性微珠为载体,选取慢性髓系白血病特异性抗原CML28作为目标抗原肽,通过抗原表位预测软件获取CML28表位序列(Vltfaedsv),并以该抗原表位与MHC分子(HLA-A2-Ig)偶联,作为第一信号分子,B7-1分子作为第二信号分子,将两种信号分子同时负载于磁珠表面,构建人工APC复合体;取HLA-A2+的健康骨髓捐赠者骨髓单个核细胞,以磁珠分选出CD8+T淋巴细胞并与人工APC复合体系统共培养。
补充资料：慢性淋巴细胞性白血病
慢性淋巴细胞性白血病
简称"慢淋"。系免疫无能的小淋巴细胞恶性增殖性疾病。起病比慢粒更缓慢，临床表现更为多样化。早期常无症状或仅有轻度不适，可在体检或血细胞检验时偶然发现。首发症状为淋巴结肿大，其次为乏力、消瘦等。全身症状如发热、盗汗、瘙痒等多为疾病进展的征象。待疾病晚期贫血及出血同时出现。本病预后相对良好，患者又多为老年，所以不必由于淋巴细胞增多而急于治疗。症状明显者，一般采用化疗和放射治疗等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条